Host immune classifier HIC assays may predict treatment response

(International Association for the Study of Lung Cancer) Using a host immune classifier (HIC) test for patients with non-small cell lung cancer (NSCLC) may provide better predictors of treatment response and improve outcomes, according to research presented today at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer Singapore.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news